Table Graph
      published meta-analysis   sensitivity analysis   studies

chloroquine and derivatives in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsBCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 1.15 [0.02; 58.61] PATCH Cohort 1 (Amaravadi), 2021 0.86 [0.02; 46.71] 1.00[0.06; 16.44]BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, PATCH Cohort 1 (Amaravadi), 202120%321moderatenot evaluable clinical deteriorationdetailed resultsPATCH Cohort 1 (Amaravadi), 2021 0.51 [0.07; 3.68] 0.51[0.07; 3.68]PATCH Cohort 1 (Amaravadi), 202110%28NAnot evaluable hospitalizationdetailed resultsBCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 0.75 [0.32; 1.76] PATCH Cohort 1 (Amaravadi), 2021 1.79 [0.06; 57.93] 0.79[0.34; 1.81]BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, PATCH Cohort 1 (Amaravadi), 202120%322moderatenot evaluable adverse eventsdetailed resultsBCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 178.20 [73.71; 430.85] 178.20[73.71; 430.85]BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 202010%353NAnot evaluable0.2500.01.0relative treatment effectwww.metaEvidence.org2024-04-18 08:09 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 508,656,657,832 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons